{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:20:03Z","timestamp":1784236803540,"version":"3.55.0"},"reference-count":355,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000092","name":"Ontario Genomics Institute","doi-asserted-by":"publisher","award":["OGI-196"],"award-info":[{"award-number":["OGI-196"]}],"id":[{"id":"10.13039\/501100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["1097737"],"award-info":[{"award-number":["1097737"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875510"],"award-info":[{"award-number":["875510"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004270","name":"Kungliga Tekniska H\u00f6gskolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bbagrm.2022.194840","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:32:54Z","timestamp":1656037974000},"page":"194840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chemical biology and pharmacology of histone lysine methylation inhibitors"],"prefix":"10.1016","volume":"1865","author":[{"given":"Samir H.","family":"Barghout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Arminda Carvalho","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Barsyte-Lovejoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagrm.2022.194840_bb0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nsmb.1842","article-title":"Post-translational modifications in signal integration","volume":"17","author":"Deribe","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pharmrev.120.000053","article-title":"E1 enzymes as therapeutic targets in cancer","volume":"73","author":"Barghout","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0015","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00018-019-03147-9","article-title":"Targeting protein methylation: from chemical tools to precision medicines","volume":"76","author":"Dilworth","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"Suppl","key":"10.1016\/j.bbagrm.2022.194840_bb0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/ng1089","article-title":"Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals","volume":"33","author":"Jaenisch","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0035","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","article-title":"Histone lysine methyltransferases in biology and disease","volume":"26","author":"Husmann","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0045","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0050","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.chemrev.8b00008","article-title":"Chemical and biochemical perspectives of protein lysine methylation","volume":"118","author":"Luo","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","article-title":"Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease","volume":"20","author":"Bhat","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41580-019-0151-1","article-title":"Roles and regulation of histone methylation in animal development","volume":"20","author":"Jambhekar","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0070","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.01.002","article-title":"Targeting histone lysine methylation in cancer","volume":"150","author":"McGrath","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/hdy.2010.49","article-title":"Epigenetic regulation of development by histone lysine methylation","volume":"105","author":"Dambacher","year":"2010","journal-title":"Heredity"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","article-title":"The roles of DNA, RNA and histone methylation in ageing and cancer","volume":"20","author":"Michalak","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/35020506","article-title":"Regulation of chromatin structure by site-specific histone H3 methyltransferases","volume":"406","author":"Rea","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nbt.2300","article-title":"New lysine methyltransferase drug targets in cancer","volume":"30","author":"Wagner","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1747-0285.2011.01135.x","article-title":"Chemogenetic analysis of human protein methyltransferases","volume":"78","author":"Richon","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tibs.2013.02.004","article-title":"Protein methylation at the surface and buried deep: thinking outside the histone box","volume":"38","author":"Clarke","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0110","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.000976","article-title":"Uncovering the human methyltransferasome","volume":"10","author":"Petrossian","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/ja056153+","article-title":"Catalytic mechanism and product specificity of the histone lysine methyltransferase SET7\/9: an ab initio QM\/MM-FE study with multiple initial structures","volume":"128","author":"Hu","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nature01378","article-title":"Structure and catalytic mechanism of the human histone methyltransferase SET7\/9","volume":"421","author":"Xiao","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.sbi.2003.10.003","article-title":"SET domains and histone methylation","volume":"13","author":"Xiao","year":"2003","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0092-8674(02)01000-0","article-title":"Structure and catalytic mechanism of a SET domain protein methyltransferase","volume":"111","author":"Trievel","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0135","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00018-006-6274-5","article-title":"SET domain protein lysine methyltransferases: Structure, specificity and catalysis","volume":"63","author":"Qian","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0140","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2016.07.014","article-title":"Chemical inhibition of protein methyltransferases","volume":"23","author":"Schapira","year":"2016","journal-title":"Cell Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41589-021-00898-0","article-title":"A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization","volume":"18","author":"Dilworth","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0150","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41589-019-0310-x","article-title":"Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3","volume":"15","author":"Bottcher","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nchembio.2306","article-title":"The EED protein\u2013protein interaction inhibitor A-395 inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","article-title":"The promise and peril of chemical probes","volume":"11","author":"Arrowsmith","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nchembio.1197","article-title":"Target validation using chemical probes","volume":"9","author":"Bunnage","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-biochem-032620-105344","article-title":"Validating small molecule chemical probes for biological discovery","volume":"91","author":"Vu","year":"2022","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccell.2017.06.005","article-title":"Choose and use your chemical probe wisely to explore cancer biology","volume":"32","author":"Blagg","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0190","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0195","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.chembiol.2021.04.007","article-title":"Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation","volume":"28","author":"Kannt","year":"2021","journal-title":"Cell Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1871520620666200410082652","article-title":"Targeted protein degradation: an emerging therapeutic strategy in cancer","volume":"21","author":"Barghout","year":"2021","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0205","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal-an attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0215","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tips.2020.02.006","article-title":"Critical assessment of targeted protein degradation as a research tool and pharmacological modality","volume":"41","author":"Kostic","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acschembio.1c00036","article-title":"The promise and peril of chemical probe negative controls","volume":"16","author":"Lee","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0225","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/ncomms4127","article-title":"The central role of EED in the orchestration of polycomb group complexes","volume":"5","author":"Cao","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gde.2016.11.001","article-title":"H3K27 methylation: a promiscuous repressive chromatin mark","volume":"43","author":"Wiles","year":"2017","journal-title":"Curr.Opin.Genet.Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-019-0615-2","article-title":"Engaging chromatin: PRC2 structure meets function","volume":"122","author":"Chammas","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0240","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","article-title":"The molecular principles of gene regulation by Polycomb repressive complexes","volume":"22","author":"Blackledge","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0245","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.molcel.2011.03.025","article-title":"Histone methylation by PRC2 is inhibited by active chromatin marks","volume":"42","author":"Schmitges","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2004.06.020","article-title":"SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex","volume":"15","author":"Cao","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0255","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature08398","article-title":"Role of the polycomb protein EED in the propagation of repressive histone marks","volume":"461","author":"Margueron","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0260","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/sj.emboj.7600402","article-title":"Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity","volume":"23","author":"Pasini","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0265","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.molcel.2018.01.039","article-title":"Unique structural platforms of Suz12 dictate distinct classes of PRC2 for chromatin binding","volume":"69","author":"Chen","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0270","series-title":"Polycomb Group Proteins","first-page":"191","article-title":"Chapter 9 - polycomb repressive complex 2 structure and function","author":"Holoch","year":"2017"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0275","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0280","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0285","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc.2016.83","article-title":"Maintaining cell identity: PRC2-mediated regulation of transcription and cancer","volume":"16","author":"Comet","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0290","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tibs.2019.04.005","article-title":"Emerging roles for polycomb-group proteins in stem cells and cancer","volume":"44","author":"Chan","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0295","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41580-021-00341-1","article-title":"The roles of Polycomb repressive complexes in mammalian development and cancer","volume":"22","author":"Piunti","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0300","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0305","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0310","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0315","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0320","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1172\/JCI70626","article-title":"Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis","volume":"123","author":"Caganova","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0325","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"Bodor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0330","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0335","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0340","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0345","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0350","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0355","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1078-0432.CCR-05-1533","article-title":"Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer","volume":"12","author":"Collett","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0360","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","article-title":"EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling","volume":"19","author":"Chang","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0370","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2007.12.005","article-title":"Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells","volume":"13","author":"Lee","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0380","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjc.6602531","article-title":"Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma","volume":"92","author":"Sudo","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0385","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0390","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-16-0164","article-title":"Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0395","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0400","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/leu.2017.300","article-title":"Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia","volume":"32","author":"Fujita","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0405","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0410","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"Sashida","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0415","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0420","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0425","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0430","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0435","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0440","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4383","article-title":"Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2","volume":"350","author":"Jiao","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0445","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0450","doi-asserted-by":"crossref","first-page":"11384","DOI":"10.1038\/ncomms11384","article-title":"Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance","volume":"7","author":"Brooun","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083737","article-title":"Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations","volume":"8","author":"Wu","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0460","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0465","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0470","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0475","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012\u20132018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0480","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/13543776.2017.1316976","article-title":"EZH2 inhibitors: a patent review(2014\u20132016)","volume":"27","author":"Stazi","year":"2017","journal-title":"Expert Opin.Ther.Patents"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0485","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0490","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/ml400494b","article-title":"Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2","volume":"5","author":"Nasveschuk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0495","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/ml3003346","article-title":"Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2","volume":"3","author":"Verma","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.126957","article-title":"Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0505","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","article-title":"EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity","volume":"6","author":"Campbell","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0510","doi-asserted-by":"crossref","first-page":"20864","DOI":"10.1038\/srep20864","article-title":"Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0515","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0520","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccell.2019.09.002","article-title":"ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures","volume":"36","author":"Qadeer","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0525","doi-asserted-by":"crossref","first-page":"12249","DOI":"10.1073\/pnas.1703966114","article-title":"PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI\/SNF mutant tumors","volume":"114","author":"Januario","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0530","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1158\/1078-0432.CCR-18-3133","article-title":"Immunologic correlates of the abscopal effect in a SMARCB1\/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy","volume":"25","author":"Gounder","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.bbagrm.2022.194840_bb0535","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1158\/1078-0432.CCR-20-4027","article-title":"Combined EZH2 inhibition and IKAROS degradation leads to enhanced antitumor activity in diffuse large B-cell lymphoma","volume":"27","author":"Tong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0540","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41388-019-1036-7","article-title":"EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1\/p53 tumor suppressor pathway","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0545","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","article-title":"Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0550","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1073\/pnas.2115116118","article-title":"CRISPR-SID: identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping","volume":"118","author":"Naert","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0555","first-page":"649","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"LancetOncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0560","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0565","first-page":"1433","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"LancetOncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0570","first-page":"1423","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"LancetOncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0575","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2020.03.042","article-title":"Epigenetic therapy for epithelioid sarcoma","volume":"181","author":"Rothbart","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0580","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11071015","article-title":"Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft","volume":"11","author":"Stacchiotti","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28772","article-title":"In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium","volume":"68","author":"Kurmasheva","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0595","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0600","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1101\/gad.1524107","article-title":"Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells","volume":"21","author":"Tan","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0605","doi-asserted-by":"crossref","first-page":"25239","DOI":"10.1038\/srep25239","article-title":"Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro","volume":"6","author":"Shen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0610","first-page":"9174926","article-title":"EZH2 inhibition ameliorates transverse aortic constriction-induced pulmonary arterial hypertension in mice","volume":"2018","author":"Shi","year":"2018","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0615","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0620","first-page":"118","article-title":"EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner","author":"Bugide","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0625","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/15384047.2019.1680061","article-title":"GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells","volume":"21","author":"Xiong","year":"2020","journal-title":"Cancer Biol.Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0630","doi-asserted-by":"crossref","first-page":"98348","DOI":"10.18632\/oncotarget.21311","article-title":"The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0635","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-21-0216","article-title":"Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines toward an ABC-like phenotype","volume":"21","author":"Preston","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0640","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","article-title":"Structure-activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0645","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0650","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41467-019-09309-4","article-title":"Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells","volume":"10","author":"Lima-Fernandes","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0655","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","article-title":"Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer","volume":"10","author":"Deblois","year":"2020","journal-title":"CancerDiscov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0660","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0665","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0670","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0675","doi-asserted-by":"crossref","first-page":"E3978","DOI":"10.1073\/pnas.1716589115","article-title":"In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis","volume":"115","author":"Wu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0680","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0685","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1158\/1078-0432.CCR-17-1533","article-title":"PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia","volume":"24","author":"Zhou","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0690","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0695","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1158\/1078-0432.CCR-18-4024","article-title":"EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy","volume":"25","author":"Puppe","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0700","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41467-018-04864-8","article-title":"Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program","volume":"9","author":"Hirukawa","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0705","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1084\/jem.20180801","article-title":"Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities","volume":"215","author":"Serresi","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0710","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","article-title":"EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0715","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of Zeste Homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin.Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0720","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0725","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0730","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.chembiol.2014.09.017","article-title":"EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation","volume":"21","author":"Bradley","year":"2014","journal-title":"Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0735","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-1697","article-title":"Abstract 1697: CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models","volume":"74","author":"Balasubramanian","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0740","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0745","doi-asserted-by":"crossref","first-page":"22733","DOI":"10.1038\/s41598-021-02181-7","article-title":"EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine","volume":"11","author":"Barazeghi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0750","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0755","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1172\/JCI99760","article-title":"Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy","volume":"128","author":"Goswami","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0760","doi-asserted-by":"crossref","first-page":"iii7","DOI":"10.1093\/annonc\/mdy048.001","article-title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","volume":"29","author":"Harb","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0765","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT094","article-title":"Abstract CT094: phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"79","author":"Taplin","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0770","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0775","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0780","doi-asserted-by":"crossref","DOI":"10.1002\/hon.14_2879","article-title":"First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas","volume":"39","author":"Ishitsuka","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0785","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood-2018-99-113379","article-title":"DS-3201, a potent EZH1\/2 dual inhibitor, demonstrates antitumor activity against non-Hodgkin lymphoma (NHL) regardless of EZH2 mutation","volume":"132","author":"Honma","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0790","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/acsmedchemlett.7b00437","article-title":"Discovery of EBI-2511: a highly potent and orally active EZH2 inhibitor for the treatment of non-Hodgkin's lymphoma","volume":"9","author":"Lu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0795","doi-asserted-by":"crossref","first-page":"8306","DOI":"10.1021\/acs.jmedchem.6b00515","article-title":"Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Kung","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0800","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13072-020-0329-y","article-title":"Inhibition of methyltransferase activity of enhancer of zeste 2 leads to enhanced lipid accumulation and altered chromatin status in zebrafish","volume":"13","author":"den Broeder","year":"2020","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0805","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0810","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-2126","article-title":"Abstract 2126: therapeutic potential of CPI-0209","volume":"81","author":"Wu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0815","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3104","article-title":"Phase 1\/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors","volume":"39","author":"Lakhani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174249","article-title":"The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0825","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0830","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0835","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acs.jmedchem.0c00479","article-title":"EEDi-5285: an exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development","volume":"63","author":"Rej","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0840","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1021\/acs.jmedchem.1c02148","article-title":"Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0845","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-19-0428","article-title":"An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0850","doi-asserted-by":"crossref","first-page":"S1113","DOI":"10.1016\/j.annonc.2021.08.855","article-title":"1525MO phase I\/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma","volume":"32","author":"Bahleda","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0855","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2021-147904","article-title":"Phase I\/II study of MAK683 in patients with advanced malignancies,including diffuse large B-Cell lymphoma","volume":"138","author":"Ribrag","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0860","first-page":"1","article-title":"Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment","author":"Zhang","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0865","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41419-022-04601-6","article-title":"Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer","volume":"13","author":"Chu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0870","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0875","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0880","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0885","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0890","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0895","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","article-title":"Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader","volume":"27","author":"Potjewyd","year":"2020","journal-title":"Cell Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0900","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1042\/BCJ20160117","article-title":"Protein lysine methylation by seven-beta-strand methyltransferases","volume":"473","author":"Falnes","year":"2016","journal-title":"Biochem.J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0905","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0092-8674(03)00114-4","article-title":"Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase","volume":"112","author":"Min","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0910","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nsmb.1432","article-title":"Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states","volume":"15","author":"Frederiks","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0915","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/leu.2014.169","article-title":"The emerging roles of DOT1L in leukemia and normal development","volume":"28","author":"McLean","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0920","doi-asserted-by":"crossref","first-page":"30421","DOI":"10.1074\/jbc.C200366200","article-title":"Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase","volume":"277","author":"Lacoste","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0925","doi-asserted-by":"crossref","DOI":"10.3390\/biom8010011","article-title":"DOT1L and H3K79 methylation in transcription and genomic stability","volume":"8","author":"Wood","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0930","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cc.28104","article-title":"The histone methyltransferase Dot1\/DOT1L as a critical regulator of the cell cycle","volume":"13","author":"Kim","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0935","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/15592294.2019.1699991","article-title":"DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment","volume":"15","author":"Sarno","year":"2020","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0940","first-page":"118","article-title":"DOT1L complex regulates transcriptional initiation in human erythroleukemic cells","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0945","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/s41467-019-10844-3","article-title":"DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation","volume":"10","author":"Godfrey","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0950","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrc3929","article-title":"Hijacked in cancer: the KMT2 (MLL) family of methyltransferases","volume":"15","author":"Rao","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0955","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0960","doi-asserted-by":"crossref","first-page":"15519","DOI":"10.1021\/acs.jmedchem.1c00872","article-title":"Recent progress of small molecule menin-MLL interaction inhibitors as therapeutic agents for acute leukemia","volume":"64","author":"Lei","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0965","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gde.2016.03.015","article-title":"The role of DOT1L in the maintenance of leukemia gene expression","volume":"36","author":"Wang","year":"2016","journal-title":"Curr.Opin.Genet.Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb0970","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0975","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0980","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature21688","article-title":"Transcription control by the ENL YEATS domain in acute leukaemia","volume":"543","author":"Erb","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0985","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0990","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb0995","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1000","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.bmc.2013.01.049","article-title":"Bromo-deaza-SAH: a potent and selective DOT1L inhibitor","volume":"21","author":"Yu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ncomms2304","article-title":"Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors","volume":"3","author":"Yu","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ccell.2014.10.009","article-title":"AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes","volume":"26","author":"Deshpande","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm.3832","article-title":"DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13148-019-0778-y","article-title":"Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer","volume":"11","author":"Yang","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1040","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1045","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/leu.2014.235","article-title":"Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro","volume":"28","author":"Sarkaria","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1050","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1038\/s41388-019-0937-9","article-title":"Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR\/Cas9","volume":"38","author":"Secker","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1055","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/0008-5472.CAN-16-1663","article-title":"The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription","volume":"77","author":"Wong","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13318-017-0404-3","article-title":"Preclinical pharmacokinetics and pharmacodynamics of pinometostat (EPZ-5676), a first-in-class, small molecule S-adenosyl methionine competitive inhibitor of DOT1L","volume":"42","author":"Waters","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1065","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-11-684225","article-title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","volume":"128","author":"Rau","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbagrm.2022.194840_bb1070","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","article-title":"DOT1L is a novel cancer stem cell target for triple negative breast cancer","volume":"28","author":"Kurani","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071972","article-title":"Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML","volume":"12","author":"Lonetti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1085","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1090","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121926","article-title":"A phase Ib\/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia","volume":"134","author":"Menghrajani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4155\/fmc.13.214","article-title":"Challenges and opportunities in targeting the menin-MLL interaction","volume":"6","author":"Cierpicki","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1105","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2012-05-429274","article-title":"Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1110","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1115","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acs.jmedchem.5b01305","article-title":"Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemia(MLL)","volume":"59","author":"Borkin","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1120","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1021\/acs.jmedchem.8b00071","article-title":"Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction","volume":"61","author":"Borkin","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010201","article-title":"Characterization of the menin-MLL interaction as therapeutic cancer target","volume":"12","author":"Brzezinka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-NB2020-120","article-title":"AML prognoses better with menin-MLL inhibitor?","volume":"11","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary data on a phase 1\/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1140","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-17-LB-A27","article-title":"Abstract LB-A27: a novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1\/DNMT3A-mutant AML","volume":"17","author":"Burrows","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1145","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2021-149831","article-title":"Clinical-stage menin inhibitor KO-539 is synergistically active with multiple classes of targeted agents in KMT2A-r and NPM1-mutant AML models","volume":"138","author":"Davis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1160","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1165","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28284","article-title":"Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium","volume":"67","author":"Kurmasheva","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2021-146944","article-title":"Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: a phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101)","volume":"138","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1180","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/jm401868d","article-title":"High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction","volume":"57","author":"He","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1185","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/anie.201711828","article-title":"Design of the first-in-class, highly potent irreversible inhibitor targeting the menin-MLL protein-protein interaction","volume":"57","author":"Xu","year":"2018","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1190","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1021\/acs.jmedchem.9b00021","article-title":"Structure-based discovery of M-89 as a highly potent inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction","volume":"62","author":"Aguilar","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1195","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1021\/acs.jmedchem.0c00547","article-title":"Discovery of M-808 as a highly potent, covalent, small-molecule inhibitor of the menin-MLL interaction with strong in vivo antitumor activity","volume":"63","author":"Xu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7020021","article-title":"Moonlighting with WDR5: a cellular multitasker","volume":"7","author":"Guarnaccia","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1205","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fonc.2018.00502","article-title":"The histone H3 lysine 4 presenter WDR5 as an oncogenic protein and novel epigenetic target in cancer","volume":"8","author":"Lu","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1210","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrd.2017.179","article-title":"WD40 repeat domain proteins: a novel target class?","volume":"16","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/BJ20121280","article-title":"Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5","volume":"449","author":"Senisterra","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1220","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1016\/j.bmc.2016.09.073","article-title":"Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc8096","article-title":"Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease","volume":"6","author":"Cao","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1230","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1021\/acs.jmedchem.1c00091","article-title":"Discovery of DDO-2213 as a potent and orally bioavailable inhibitor of the WDR5-mixed lineage leukemia 1 protein-protein interaction for the treatment of MLL fusion leukemia","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.molcel.2013.12.001","article-title":"Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia","volume":"53","author":"Cao","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1240","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1021\/acs.jmedchem.6b01796","article-title":"Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)-mixed lineage leukemia (MLL) protein-protein interaction","volume":"60","author":"Karatas","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1245","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nchembio.1859","article-title":"Pharmacological targeting of the Wdr5-MLL interaction in C\/EBP\u03b1 N-terminal leukemia","volume":"11","author":"Grebien","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1250","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/acs.jmedchem.5b01630","article-title":"Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5(WDR5) and mixed-lineage leukemia 1 (MLL1)","volume":"59","author":"Getlik","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1255","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1186\/s12885-018-4580-6","article-title":"WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage","volume":"18","author":"Neilsen","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1260","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1038\/s41467-019-11696-7","article-title":"Genotoxic stress-triggered beta-catenin\/JDP2\/PRMT5 complex facilitates reestablishing glutathione homeostasis","volume":"10","author":"Cao","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1265","doi-asserted-by":"crossref","first-page":"eabj1578","DOI":"10.1126\/scitranslmed.abj1578","article-title":"A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models","volume":"13","author":"Yu","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1270","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1021\/acs.jmedchem.1c00146","article-title":"Design, synthesis, and evaluation of WD-repeat-containing protein 5 (WDR5) degraders","volume":"64","author":"Dolle","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1275","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1101\/gad.476008","article-title":"A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse","volume":"22","author":"Schotta","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1280","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1101\/gad.300704","article-title":"A silencing pathway to induce H3\u2013K9 and H4\u2013K20 trimethylation at constitutive heterochromatin","volume":"18","author":"Schotta","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1285","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/nar\/gkt012","article-title":"Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity","volume":"41","author":"Jorgensen","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1290","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2282","article-title":"The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity","volume":"13","author":"Bromberg","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1295","doi-asserted-by":"crossref","first-page":"17973","DOI":"10.1074\/jbc.RA120.015533","article-title":"Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells","volume":"295","author":"Vilema-Enriquez","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1300","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1038\/s41467-021-22665-4","article-title":"DNMT1 reads heterochromatic H4K20me3 to reinforce LINE-1 DNA methylation","volume":"12","author":"Ren","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1305","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.molcel.2010.10.011","article-title":"Regulation of the histone H4 monomethylase PR-Set7 by CRL4(Cdt2)-mediated PCNA-dependent degradation during DNA damage","volume":"40","author":"Oda","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1310","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-022-01251-5","article-title":"Roles for the methyltransferase SETD8 in DNA damage repair","volume":"14","author":"Xu","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1315","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/cmdc.201600272","article-title":"Progress in the development of lysine methyltransferase SETD8 inhibitors","volume":"11","author":"Milite","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/ol303416k","article-title":"Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8","volume":"15","author":"Williams","year":"2013","journal-title":"Org. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1325","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1021\/jm500871s","article-title":"Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8","volume":"57","author":"Ma","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1330","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ccell.2016.12.002","article-title":"Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma","volume":"31","author":"Veschi","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1335","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/acs.jmedchem.6b01244","article-title":"Structure-based design of a covalent inhibitor of the SET domain-containing protein 8 (SETD8) lysine methyltransferase","volume":"59","author":"Butler","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1340","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/febs.15844","article-title":"The duality of PRDM proteins: epigenetic and structural perspectives","volume":"289","author":"Di Tullio","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1345","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tig.2017.12.017","article-title":"PRDM9 and its role in genetic recombination","volume":"34","author":"Paigen","year":"2018","journal-title":"Trends Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1350","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1038\/s41467-019-13652-x","article-title":"Discovery of a chemical probe for PRDM9","volume":"10","author":"Allali-Hassani","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1355","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1101\/gad.1284005","article-title":"Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3\u2013K9","volume":"19","author":"Tachibana","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1360","doi-asserted-by":"crossref","first-page":"20120","DOI":"10.1074\/jbc.M603087200","article-title":"Zinc finger protein Wiz links G9a\/GLP histone methyltransferases to the co-repressor molecule CtBP","volume":"281","author":"Ueda","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1365","article-title":"The zinc finger proteins ZNF644 and WIZ regulate the G9a\/GLP complex for gene repression","volume":"4","author":"Bian","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1370","doi-asserted-by":"crossref","DOI":"10.3390\/life11101082","article-title":"Structure, activity, and function of the protein lysine methyltransferase G9a","volume":"11","author":"Poulard","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1375","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1158\/0008-5472.CAN-06-0101","article-title":"Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1380","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1385","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1390","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1395","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/ml400496h","article-title":"Discovery and development of potent and selective inhibitors of histone methyltransferase g9a","volume":"5","author":"Sweis","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1400","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/cb300139y","article-title":"A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma","volume":"7","author":"Yuan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1405","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1021\/acs.jmedchem.6b01645","article-title":"Discovery of potent and selective inhibitors for G9a-like protein (GLP) lysine methyltransferase","volume":"60","author":"Xiong","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1410","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.2027411","article-title":"H3K9 methyltransferase G9a and the related molecule GLP","volume":"25","author":"Shinkai","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1415","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood-2015-02-629972","article-title":"Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR\/gamma-globin looping","volume":"126","author":"Krivega","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1420","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1097-2765(01)00405-1","article-title":"Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase","volume":"8","author":"Wang","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1425","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature03117","article-title":"Regulation of p53 activity through lysine methylation","volume":"432","author":"Chuikov","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1430","doi-asserted-by":"crossref","first-page":"26771","DOI":"10.1074\/jbc.M802800200","article-title":"Role of the histone H3 lysine 4 methyltransferase, SET7\/9, in the regulation of NF-kappaB-dependent inflammatory genes.Relevance to diabetes and inflammation","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1435","doi-asserted-by":"crossref","first-page":"12770","DOI":"10.1074\/jbc.RA118.002890","article-title":"Identification of Rpl29 as a major substrate of the lysine methyltransferase Set7\/9","volume":"293","author":"Hamidi","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1440","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.molcel.2011.08.006","article-title":"p53-dependent transcription and tumor suppression are not affected in Set7\/9-deficient mice","volume":"43","author":"Lehnertz","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1445","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061414","article-title":"A systematic review to define the multi-faceted role of lysine methyltransferase SETD7 in cancer","volume":"14","author":"Monteiro","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1450","doi-asserted-by":"crossref","DOI":"10.3390\/life12030362","article-title":"The role of lysine methyltransferase SET7\/9 in proliferation and cell stress response","volume":"12","author":"Daks","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1455","doi-asserted-by":"crossref","first-page":"12853","DOI":"10.1073\/pnas.1407358111","article-title":"(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells","volume":"111","author":"Barsyte-Lovejoy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1460","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nature13320","article-title":"SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer","volume":"510","author":"Mazur","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1465","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","article-title":"Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease","volume":"20","author":"Bhat","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1470","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1475","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrm3274","article-title":"Understanding the language of Lys36 methylation at histone H3","volume":"13","author":"Wagner","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1480","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tibs.2014.09.001","article-title":"Structure and function of the nucleosome-binding PWWP domain","volume":"39","author":"Qin","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1485","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/0008-5472.CAN-13-1000","article-title":"NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1490","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026708","article-title":"The role of nuclear receptor-binding SET domain family histone lysine methyltransferases in cancer","volume":"7","author":"Bennett","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051029","article-title":"Roles of SETD2 in leukemia-transcription, DNA-damage, and beyond","volume":"20","author":"Skucha","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1500","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1093\/emboj\/cdg288","article-title":"NSD1 is essential for early post-implantation development and has a catalytically active SET domain","volume":"22","author":"Rayasam","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1505","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature08086","article-title":"A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome","volume":"460","author":"Nimura","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1510","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc3884","article-title":"Critical roles of non-histone protein lysine methylation in human tumorigenesis","volume":"15","author":"Hamamoto","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1073\/pnas.0912493107","article-title":"Regulation of NF-kappaB by NSD1\/FBXL11-dependent reversible lysine methylation of p65","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1520","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-03069-8","article-title":"Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases","volume":"590","author":"Li","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1525","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng863","article-title":"Haploinsufficiency of NSD1 causes Sotos syndrome","volume":"30","author":"Kurotaki","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1530","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1086\/345647","article-title":"NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes","volume":"72","author":"Douglas","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1535","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/383093","article-title":"Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome","volume":"74","author":"Baujat","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1540","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2011.11.018","article-title":"Mutations in EZH2 cause Weaver syndrome","volume":"90","author":"Gibson","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1545","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.gde.2005.04.007","article-title":"Mechanisms predisposing to childhood overgrowth and cancer","volume":"15","author":"Rahman","year":"2005","journal-title":"Curr.Opin.Genet.Dev."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1550","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V98.4.1264","article-title":"A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia","volume":"98","author":"Jaju","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1555","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1038\/sj.leu.2403104","article-title":"Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia","volume":"17","author":"Cerveira","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1560","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1565","first-page":"683","article-title":"NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia","volume":"52","author":"Shiba","year":"2013","journal-title":"GenesChromosomesCancer"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1570","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2016.267","article-title":"NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis","volume":"31","author":"Struski","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1575","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/hmg\/7.7.1071","article-title":"WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma","volume":"7","author":"Stec","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1580","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/hmg\/6.2.317","article-title":"A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region","volume":"6","author":"Wright","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1585","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41436-021-01158-1","article-title":"Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype","volume":"23","author":"Zanoni","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1590","article-title":"Genotype-phenotype characterization of Wolf-Hirschhorn syndrome confirmed by FISH: case reports","volume":"2012","author":"Sheth","year":"2012","journal-title":"Case Rep.Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1595","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12185-020-03005-6","article-title":"Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents","volume":"113","author":"Sato","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1600","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/TACG.S262866","article-title":"Genetic predictors of mortality in patients with multiple myeloma","volume":"14","author":"Hassan","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1605","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/leu.2013.204","article-title":"Point mutation E1099K in MMSET\/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies","volume":"28","author":"Oyer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1610","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1158\/1541-7786.MCR-20-0092","article-title":"The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell context-dependent manner in pediatric acute lymphoblastic leukemia","volume":"18","author":"Pierro","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1615","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1620","first-page":"6837","article-title":"The role of methyltransferase NSD2 as a potential oncogene in human solid tumors","volume":"13","author":"Chen","year":"2020","journal-title":"OncoTargetsTher."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1625","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.molcel.2012.10.008","article-title":"Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer","volume":"49","author":"Asangani","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004566","article-title":"Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation","volume":"10","author":"Popovic","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1635","article-title":"Identification of druggable cancer driver genes amplified across TCGA datasets","volume":"9","author":"Chen","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1640","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1645","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.18632\/oncotarget.2967","article-title":"Genetic alterations of histone lysine methyltransferases and their significance in breast cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/0008-5472.CAN-20-0360","article-title":"NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression","volume":"81","author":"Jeong","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1655","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood.V99.10.3857","article-title":"NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15)","volume":"99","author":"Rosati","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cancergencyto.2008.12.008","article-title":"NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes","volume":"190","author":"Taketani","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1665","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1670","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.molcel.2018.11.006","article-title":"Interactome rewiring following pharmacological targeting of BET bromodomains","volume":"73","author":"Lambert","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1675","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41589-020-0626-6","article-title":"Covalent inhibition of NSD1 histone methyltransferase","volume":"16","author":"Huang","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1680","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.1074\/jbc.M116.720748","article-title":"A PWWP domain of histone-lysine N-methyltransferase NSD2 binds to dimethylated Lys-36 of histone H3 and regulates NSD2 function at chromatin","volume":"291","author":"Sankaran","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1685","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.chembiol.2021.08.004","article-title":"A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells","volume":"29","author":"Xu","year":"2022","journal-title":"Cell Chem.Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1690","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1695","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1700","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13148-021-01160-z","article-title":"Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma","volume":"13","author":"Herviou","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1705","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cmet.2013.11.004","article-title":"The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation","volume":"18","author":"Ding","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1710","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4161\/auto.26308","article-title":"BIX-01294 induces autophagy-associated cell death via EHMT2\/G9a dysfunction and intracellular reactive oxygen species production","volume":"9","author":"Kim","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1715","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/nar\/gky1230","article-title":"FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer","volume":"47","author":"Chae","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1720","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3389\/fonc.2020.00818","article-title":"Increased efficacy of histone methyltransferase G9a inhibitors against MYCN-amplified neuroblastoma","volume":"10","author":"Bellamy","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1725","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41401-018-0205-5","article-title":"Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells","volume":"40","author":"Cao","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4257","article-title":"Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome","volume":"23","author":"Kim","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1735","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57683","article-title":"EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma","volume":"9","author":"Pal","year":"2020","journal-title":"elife"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1740","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1038\/s41388-021-01799-1","article-title":"Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6","volume":"40","author":"Zhou","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1745","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","article-title":"Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression","volume":"25","author":"Segovia","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131716","article-title":"The histone methyltransferase inhibitor A-366 uncovers a role for G9a\/GLP in the epigenetics of leukemia","volume":"10","author":"Pappano","year":"2015","journal-title":"PloS one"},{"key":"10.1016\/j.bbagrm.2022.194840_bb1755","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.191","article-title":"Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells","volume":"4","author":"Yuan","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1760","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1541-7786.MCR-19-0490","article-title":"Combined targeting of G9a and checkpoint kinase 1 synergistically inhibits pancreatic cancer cell growth by replication fork collapse","volume":"18","author":"Urrutia","year":"2020","journal-title":"Mol.Cancer Res."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1765","doi-asserted-by":"crossref","first-page":"12853","DOI":"10.1073\/pnas.1407358111","article-title":"(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells","volume":"111","author":"Barsyte-Lovejoy","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1770","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2282","article-title":"The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity","volume":"13","author":"Bromberg","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbagrm.2022.194840_bb1775","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ng.3466","article-title":"Exploring genomic alteration in pediatric cancer using ProteinPaint","volume":"48","author":"Zhou","year":"2016","journal-title":"Nat. Genet."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874939922000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874939922000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:09:25Z","timestamp":1778828965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874939922000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":355,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1874939922000554"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagrm.2022.194840","relation":{},"ISSN":["1874-9399"],"issn-type":[{"value":"1874-9399","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical biology and pharmacology of histone lysine methylation inhibitors","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagrm.2022.194840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"194840"}}